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Abstract: To explore whether the magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) loaded 
with cisplatin can reverse the diaminedichloro platinum (DDP) resistance to multidrug resis-
tance of ovarian carcinoma cells and to investigate its mechanisms. The SKOV3/DDP cells 
were divided into DDP treatment (DDP group), MNPs-Fe3O4 treatment (MNPs-Fe3O4 group), 
DDP + MNPs-Fe3O4 treatment (DDP + MNPs-Fe3O4 group), and control group. After incubation 
with those conjugates for 48 h, the cytotoxic effects were measured by MTT assay. Apoptosis 
and the intracellular DDP concentration were investigated by flow cytometry and inductively 
coupled plasma atomic emission spectroscopy, respectively. The expression of apoptosis associ-
ated gene Bcl-2 mRNA was detected by reverse transcription polymerase chain reaction and 
the expressions of MDR1, lung resistance-related protein (LRP), and P-glycoprotein (P-gp) 
genes were studied by Western blot. Our results indicated that the 50% inhibition concentration 
(IC50) of the MNPs-Fe3O4 loaded with DDP was 17.4 µmol/ l, while the IC50 was 39.31 µmol/l 
in DDP groups (p  0.05); Apoptosis rates of SKOV3/DDP cells increased more than those 
of DDP groups. Accumulation of intracellular cisplatin in DDP + MNPs-Fe3O4 groups was 
higher than those in DDP groups (p  0.05). Moreover, the expression of Bcl-2 mRNA and 
the protein expressions of MDR1, LRP, and P-gp were decreased when compared with those of 
DDP groups, respectively. Our results suggest that MNPs-Fe3O4 can reverse the DDP resistance 
to the ovarian carcinoma cell. The effects may be associated with over-expression of MDR1, 
LRP, P-gp, and Bcl-2, which can increase the intracellular platinum accumulation and induce 
the cell apoptosis.
Keywords: magnetic nanoparticles of Fe3O4, multidrug resistance reversal, SKOV3/DDP, 
MDR1, LRP, P-gp, Bcl-2
Introduction
Ovarian cancer is the leading cause of death from gynecologic malignancies and the 
fourth most common cause of death due to cancer among women. Treatment for ovarian 
cancer includes maximal cytoreductive surgery followed by combination chemotherapy. 
Unfortunately, the initial response rate is not durable; the majority will experience disease 
recurrence. The poor five-year survival rates seen in epithelial ovarian cancer are at least 
partly attributed to the development of platinum resistance.1 A major clinical obstacle 
in cancer therapy is the development of resistance to a multitude of chemotherapeutic 
agents, a phenomenon called multidrug resistance (MDR). Cisplatin (cis-diaminedichloro 
platinum [CDDP]) is one of the most potent antitumor agents to display high efficiency 
in the treatment of ovarian and testicular cancer. CDDP exerts its cytotoxity on ovarian 
cancer and induces apoptosis.2 Resistance to CDDP remains a major obstacle for the International Journal of Nanomedicine 2009:4 108
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successful treatment of cancer. The mechanisms of CDDP 
resistance include reduced drug accumulation by changing the 
profile of uptake/efflux, inactivation of CDDP by increased 
levels of the intracellular thiols such as glutathione, metallo-
thionein, or other sulfur-containing molecules, increased repair 
of CDDP adducts, increased tolerance to CDDP adducts, and 
failure of apoptotic response.
Reduced intracellular CDDP accumulation in resis-
tant cells may ascribe to an inhibition of CDDP uptake, 
an increase in drug efflux, or both. Multidrug transporter 
P-glycoprotein (P-gp), which is encoded by the MDR1 gene, 
is a major organic action transporter in tissues responsible 
for the excretion of xenobiotics (both drugs and toxins) by 
the biliary tract and proximal tubule of the kidney.3 P-gp 
functions as transmembrane drug efflux pumps, decreasing 
intracellular drug accumulation. Lung resistance-related 
protein (LRP) is another MDR-related protein.
Human ovarian adenocarcinoma cells (SKOV3), 
detected by high expression of 110-kDa LRP protein and 
over-expression of P-gp,4 were incubated in a medium 
containing DDP to maintain the resistant characteristics. 
Clinical studies have demonstrated that the increased level of 
LRP/major vault protein (MVP) may be an important factor 
contributing to intrinsic CDDP resistance in SKOV3 cells.5
Apoptosis is a key determinant of chemosensitivity in 
ovarian cancer.6–9 It has been widely accepted that apoptosis 
is an active gene-directed cellular suicide mechanism and 
many human genes contribute to the regulation. Among them, 
Bcl-2 families draw particular attention because it is one of 
the key factors of the common final pathway involved in 
the regulation of cell apoptosis. Recent studies showed that 
over-expression of Bcl-2 caused increased MDR in cancerous 
cells. In the SKOV3/DDP cell line, over-expression of Bcl-2 
was demonstrated but not in SKOV3 cell line alone.10
In spite of the mechanism for MDR being unveiled 
incompletely, avoiding the appearance of drug resistance and 
modulation of the MDR has been a great challenge to cancer 
therapy in the laboratory and clinic. Much effort has been 
extended to efficient cancer therapies. Unfortunately, many 
approved treatments for ovarian cancer have accumulative 
toxicities that leave patients more susceptible to adverse 
events during subsequent lines of therapy. It is generally 
accepted that any treatment which could increase the effec-
tive concentration of an intracellular chemotherapeutic agent 
should be pursued.11
Recently, the application of drug-coated polymer 
nanospheres and nanoparticles to inhibit related MDR has 
drawn much attention. As a promising drug delivery system, 
magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) have been 
studied for some years in our group.11–12 In our previous 
studies, we prepared MNPs-Fe3O4 loaded with Adriamycin 
(ADM) and/or tetrandrine (Tet) to reverse MDR of K562/A02 
cells. The cytotoxicity test in vitro revealed that MNPs-Fe3O4 
exhibited excellent biocompatibility.13–14 In previous work by 
our group,12 we found that MNPs-Fe3O4 loaded with ADM 
could enhance the effective accumulation of ADM in K562/
A02 cells. It is demonstrated that ADM polymerized with 
MNPs-Fe3O4 have shown more chemosensitizing activities 
than those of ADM alone.
In this work, we present an evaluation of the potential 
of MNPs-Fe3O4 as a candidate agent for treatment of ovar-
ian cancer and to investigate the role of MDR1, LRP, P-gp, 
and Bcl-2 in intracellular platinum accumulation and cell 
apoptosis.
Materials and methods
cell line and cell culture
The MDR human ovarian cancer cell line, SKOV3/DDP, was 
obtained from the Chinese Academy of Medical Sciences and 
Peking Union Medical College. The SKOV3/DDP cell line was 
cultured in a flask in RPMI-1640 containing 10% fetal bovine 
serum (FBS; Gibco, Carlsbad, CA), 2 µmol/l l-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco BRL, 
Grand Island, NY) at 37 °C, 5% CO2 with high humidity. For 
the maintenance of the MDR phenotype, 2 µg/ml cisplatin 
(Sigma Aldrich, St. Louis, MO) was added to the medium, 
which was passaged every 2∼3 days using 0.05% trypsin 
(Gibco BRL) and 0.01% EDTA (Sigma Aldrich).
Preparation of drug-loaded nanoparticles
The synthesis of MNPs-Fe3O4 was prepared by electrochemical 
deposition under oxidizing conditions (EDOC) based on 
our previous studies.11–12 Before application in the present 
experiment, the magnetic nanoparticles were well distributed 
in RPMI-1640 medium (Sigma Aldrich) with 10% heated 
inactivated FBS freshly added by using ultrasound treat-
ment in order to obtain MNPs-Fe3O4 colloidal suspension. 
CDDP conjugated with MNPs-Fe3O4 (DDP + MNPs-Fe3O4) 
was prepared by mechanical absorption polymerization as 
previously reported.15 The temperature effect was also inves-
tigated and a temperature of 37 °C or 4 °C was chosen for 
our polymerization process. Briefly, different concentrations 
(V/V) of 25 µg/ml MNPs-Fe3O4 were respectively added 
under mechanical stirring to 200 µl of an aqueous medium 
with 20 µmol/l DDP that, in the final nanoparticle and cell sus-
pension, was 50 µmol/l (pH = 7.4). At different temperatures International Journal of Nanomedicine 2009:4 109
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(37 °C, 4 °C), the overall polymerization process lasted for 
24 h. The RPMI-1640 medium was regarded as blank control 
and cells with no intervention were negative control.
MTT assay
For cell growth and viability assays, 5 × 104/ml cells were 
plated into Six-well flat-bottomed plates (Costar, Charlotte, 
NC), respectively. Different concentrations of DDP, MNPs-
Fe3O4, and MNPs-Fe3O4 loaded with DDP or RPMI-1640 
were added into these cells and cultured to measure their 
growth and viability. Based on these results, different 
concentrations of DDP and MNPs-Fe3O4 were combined to 
find the best combination concentration which can best kill 
tumor cells. After incubation for 48 h, 20 µl MTT solution 
(5 mg/ml)was added into each well at 37 °C in the dark for 
at least 4 h. Formazan crystals were solubilized in 200 µl 
dimethyl sulfoxide (DMSO) in every well and the reduc-
tion of MTT was quantified by absorbance at 540 nm using 
a plate reader (Model 550; Bio-Rad, Tokyo, Japan). The 
inhibition ratio of cells was determined as follows (1-A of 
tests cells/A of black control) × 100%. Each assay was 
repeated at least three times.
Annexin V–PI assays for apoptosis
As described before, cells were incubated and harvested. For 
Annexin V–propidium iodide (PI) assays, cells were stained 
and evaluated for apoptosis by flow cytometry according 
to the manufacturer’s protocol. Briefly, 1 × 106 cells were 
stained with 5 µl Annexin V–fluorescein isothiocyanate 
(FITC) and 10 µl PI (5 µg/ml) in 1 × binding buffer (1.0 
mmol/L HEPES [4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid], pH = 7.4, 140 mmol/L NaOH, 2.5 mmol/L CaCl2) 
for 20 min at room temperature in the dark. The apoptotic 
cells were determined using flow cytometry (FACSCali-
bur™; Becton-Dickinson, Franklin Lakes, NJ).
Measurement of intracellular  
DDP accumulation
Briefly, cells (5 × 104/ml) were incubated with DDP, MNPs-
Fe3O4, MNPs-Fe3O4 loaded with DDP or RPMI-1640 medium 
for 48 h at 37 °C in humidified 5% CO2 atmosphere. After 
incubation, an aliquot was taken, washed twice with 2 mol/l 
iced-cold isotonic buffer, the pellet was resuspended in 33% 
HNO3, and then the DDP content was determined by induc-
tively coupled plasma atomic emission spectroscopy (ICP-
AES) in SPECTRO GENESIS SOP (SPECTRO Analytical 
Instruments, Marble Falls, TX) equipment.
Reverse transcription polymerase  
chain reaction
As described before, cells seeded at a density of 5 × 104 cells/well 
in 6-well plates were treated with one of the following 
treatments: (a) DDP + MNPs-Fe3O4, (b) DDP, (c) MNPs-
Fe3O4, (d) RPMI-1640 for 48 h, and harvested. Cells were 
dissolved in TRIzol reagent (Gibco BRL). Total RNA was 
extracted according to the manufacturer’s instructions. The 
RNA A260/A280 ratios were between 1.6 and 1.8. The primers 
for human Bcl-2 (forward: 5’-GGGAGAACAGGGTAC 
GATAA-3’; reverse: 5’-CCACCGAACT CAAAGAAGG-3’), 
and β-actin (forward: 5’-TATGACTTAGTTGC GTTA-
CACC-3’; reverse: 5’-CCTTCAC CGTTCCAGTTT-3’) were 
used. The amplified polymerase chain reaction (PCR) products 
were 452 bp and 155 bp, respectively. The copy number for 
each sample was calculated and all the data were normalized 
to β-actin. Briefly, cDNA was synthesized from 1 µg of total 
cellular RNA using TaKaRa RNA PCR kit (AMV) (Ver. 3.0; 
Dalian, China). The newly synthesized cDNA was amplified 
by PCR (TaKaRa). The PCR conditions were 95 °C for 3 min 
and 35 cycles of 95 °C for 30 s, 56 °C for 30 s, and 72 °C for 
1 min. Control amplifications were conducted either without 
reverse transcription (RT) or without RNA. Following PCR 
amplification, the reaction products were electrophoresed at 
100 V on 1.5% agarose gels with 0.5 µg/ml ethidium bromide 
(Sigma Aldrich)16 and PCR fragments were visualized by UV 
illumination (GDS7500 Gel; UVP Inc., Upland, CA, USA). 
Densitometric analysis was performed using the electropho-
resis image analysis system Smart View 2000 software (Furi, 
Shanghai, China).
Western blot
SKOV3/DDP cells were treated with DDP, MNPs-Fe3O4, 
DDP + MNPs-Fe3O4, and RPMI-1640 medium for 48 h, 
respectively. Whole cell extracts were harvested on ice, 
washed in phosphate-buffered saline (PBS), and lysed in 
100 ml of lysis buffer (30 mM Tris, pH 7.5, 150 mM NaCl, 
1 mM PMSF, 1 mM Na3VO4, 1% Nonidet P-40, and 10% 
glycerol) for 30 min at 48 °C, then centrifuged at 14,000 r/min 
for 10 min. The supernatant was collected and the amount 
of protein was measured using Bio-Rad protein assay 
(Bio-Rad, Hercules, CA). Equals amount (25 mg) of protein 
from each sample was separated in 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
gels using modified radio immunoprecipitation assay (RIPA) 
buffer and transferred the proteins to a nitrocellulose mem-
brane (Bio-Rad). Western blotting was performed with a 
1:500–1:1,000 dilutions of monoclonal antibodies against International Journal of Nanomedicine 2009:4 110
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either anti-human P-gp (NeoMarkers, Fremont, CA), MDR1 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), LRP (Santa 
Cruz Biotechnology Inc.) or β-action anti-body (Santa Cruz 
Biotechnology Inc.) in 5% nonfat dry milk, followed by 
peroxidase-conjugated IgG-HRP (Santa Cruz Biotechnology 
Inc.) as a secondary antibody (peroxidase-conjugated swine 
anti-rabbit).The blots were developed by enhanced chemilu-
minescence (ECL system, Amersham, UK).
statistical analysis
All data were presented as means ± standard deviation in 
triplicate. All analyses were performed with Statistical 
Package for Social Science (SPPS Release 11.5; SPSS Inc., 
IL, USA). Differences were evaluated using Student’s t-test 
or paired t-test and considered statistically significant for 
values of p  0.05.
Results
cell growth and inhibition
The MTT assay revealed that the growth and inhibition of 
DDP, MNPs-Fe3O4, or DDP + MNPs-Fe3O4 to SKOV3/DDP 
cells (as shown in Figures 1, 2). It was indicated that MNPs-
Fe3O4 alone could hardly inhibit SKOV3/DDP cell prolif-
eration when their doses were between 12.5 µg to 75 µg 
(p  0.05) (Figure 1). SKOV3/DDP cells were significantly 
resistant to DDP when the concentration of DDP was not 
less than 10 µmol/l. The inhibition of SKOV3/DDP cells 
was in a dose-dependent manner and the 50% inhibition 
concentration (IC50) was 39.31 µmol/l. Furthermore, we 
found the optimum concentration of MNPs-Fe3O4 was 25 
µg/ml from a different concentration of MNPs-Fe3O4 loaded 
with a different concentration of DDP. The inhibition of 
SKOV3/DDP cells in MNPs-Fe3O4 loaded with DDP group 
was significantly higher than that in DDP group and the 
IC50 of MNPs-Fe3O4 loaded with DDP was 17.4 µmol/l, 
which was 2.259-fold lower than that in the DDP groups 
(p  0.05), suggesting that the reverse rate was 2.259 
(Figure 2).
Annexin V–PI assays for apoptosis
Annexin V–PI double-staining assays demonstrated that 
MNPs-Fe3O4 could hardly induce apoptosis of SKOV3/DDP 
cells compared to control group (p  0.05). Only (4.4% ± 0.36%) 
apoptosis of SKOV3/DDP cells were observed under MNPs-
Fe3O4. When DDP was loaded with MNPs-Fe3O4, apoptosis 
rates of SKOV3/DDP cells in the DDP+MNPs-Fe3O4 group 
was significantly higher than that in DDP group alone 
(p  0.05). The apoptosis rates were (42.07% ± 5.55%) and 
(26.93% ± 4.11%), respectively. There were all statistically 
significant when compared with (6.83% ± 0.64%) in the 
control group (p  0.05) (Figure 3).
Intracellular DDP concentration
The intracellular DDP concentration in cells was explored 
by ICP-AES analysis when the SKOV3/DDP cells were 
incubated for 48 h.The intracellular DDP concentration of 
SKOV3/DDP cells in DDP with or without MNPs-Fe3O4 
groups was founded to increase by (0.057 ± 0.003 µmol/l) 
and (0.074 ± 0.006 µmol/l), respectively. There were statis-
tically significant differences between them when compared 
(p  0.05) (Table 1).
RT-PcR for Bcl-2 mRNA
Based on computer-assisted image analysis, it appeared 
that single use of MNPs-Fe3O4 had no obvious effect 
on Bcl-2 mRNA in SKOV3/DDP cells (p  0.05), but 
DDP + MNPs-Fe3O4 reinforced downregulation of Bcl-2 
mRNA content significantly (p  0.05), causing a 70-fold 
more decrease in Bcl-2 mRNA level and single use of 
DDP had less downregulation than the same concentration 
Table 1 Intracellular accumulation of DDP in sKOV3/DDP cells 
incubating with DDP or MNPs-Fe3O4 for 48 h
Group Intracellular DDP (µ mol/l)
DDP 0.057 ± 0.003
DDP + MNPs-Fe3O4 0.074 ± 0.006*
Note: *p  0.05, compared with DPP (signal factor analysis of variance).
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Figure 1 growth inhibition rates of sKOV3/DDP cells incubating with different 
concentrations of MNPs-Fe3O4 for 48 h by MTT assay.
Note: p  0.05, when the concentration of MNPs-Fe3O4 is less than 75 µg (signal 
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of DDP polymerized with MNPs-Fe3O4 (p  0.05), 
suggesting that MNPs-Fe3O4 can enhance the action of 
DDP in downregulation of Bcl-2 mRNA in SKOV3/DDP 
cells (Figure 4).
Western blot
In order to examine the expression of the P-gp, LRP, 
and MDR1, we next performed Western blot analysis 
on whole cell protein extracts from cells treated for 48 h 
as described previously (Figure 5). Based on computer-
assisted image analysis, it appeared that MNPs-Fe3O4 
themselves could not lower the protein of P-gp, LRP, and 
MDR1 in SKOV3/DDP cells (p  0.05), but they could 
downregulate the expression of P-gp, LRP, and MDR1 
protein levels when loaded with DDP. We also found that 
the expressions of protein in DDP + MNPs-Fe3O4 group 
were lower than those in DDP-alone groups (p  0.05), 
suggesting that MNPs-Fe3O4 can enhance the accumulation 
of DDP in SKOV3/DDP cells.
Discussion
It is well known that intrinsic and/or acquired chemoresis-
tance is the major obstacle for successful treatment of patients 
with ovarian carcinoma.17 A low five-year overall survival 
rate of only 53% for woman suffering from ovarian cancer 
is related to the development of resistance of tumor cells to 
standard chemotherapeutic agents.18–19 Cisplatin was the first 
platinum-containing compound introduced into therapeutic 
trials for ovarian cancer. Resistance to cisplatin-based che-
motherapy is a major cause of treatment failure in human 
ovarian cancer. Both intrinsic and acquired resistance to 
cisplatin occurs frequently.
Many studies have shown that the development of drug 
resistance of cancer cells is related to inhibition of cell apop-
tosis. Moreover, the apoptotic rate increased with the concen-
tration of cisplatin, suggesting that cisplatin induced apoptosis 
in a dose-dependent fashion. So, the first step to successful 
reversal drug resistance is to increase cisplatin concentrations 
in the ovarian cancer cell. Nanotechnology and nanoscience 
have developed rapidly during the last few decades. The most 
important clinical application of nanotechnology is probably 
in pharmaceutical development.20 As demonstrated previously 
and as observed in this study, the intracellular cisplatin levels 
in DDP + MNPs-Fe3O4 groups were found to be higher than 
those of DDP-alone groups, suggesting that MNPs-Fe3O4 can 
increase cisplatin concentration in SKOV3/DDP cells and 
enhance the effective accumulation of anticancer agents in 
resistant cancer cells. We also found that the apoptosis rates of 
SKOV3/DDP cells were increased than those of DDP groups. 
All of these suggested that MNPs-Fe3O4 could reverse the DDP 
resistance to the ovarian carcinoma cell (SKOV3/DDP), and 
the effects are ascribed to increase the intracellular DDP accu-
mulation, and to induce appoptosis, which were demonstrated 
by flow cytometry.
As one of the most commonly used magnetic nanoparti-
cles, MNPs-Fe3O4 are obtained more easily than other MNPs 
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and they may aggregate in water or tissue fluid spontaneously 
with good biocompatibility and low toxicity,21–23 which 
suggests MNPs-Fe3O4 were safe for the use of drug carriers. 
Moreover, MNPs-Fe3O4 are found readily to interact with 
proteins.24 The mechanism of MNPs-Fe3O4 in increasing the 
effective intracelluar concentration of DDP is still unclear. 
Nanoparticles loaded with an anticancer drug could readily 
approach the cell membrane, leading to drug concentra-
tions at the cell surface higher than those obtained with the 
same amount of drug diluted in a culture medium, leading 
in turn to higher intracellular drug concentration.25–26 Not 
only have MNPs-Fe3O4 the ability to block P-gp func-
tion, but they also have potency in aggregation and drug-
capsulation.27–28 The expression of P-gp and MDR-related 
proteins are associated with a poor prognosis in patients 
with ovarian cancer. P-gp and MDR protein (MRP) are 
known to be associated with MDR. P-gp, an integral 
membrane glycoprotein with a molecular mass of 170 kd, 
has been postulated to function as a pump to remove 
hydrophobic anticancer agents from drug-resistant cells. 
MRP, a 190-kd 1531-amino-acid membrane glycoprotein, 
is over-expressed in most non-P-gp-mediated multidrug 
resistant cell lines. MRP and P-gp are members of the 
adenosine triphosphate (ATP)-binding cassette super-
family of membrane transporter proteins. It is generally 
accepted that increased levels of P-gp expression have 
been observed in some tumors at the time of relapse after 
initial chemotherapy. The 110-kd LRP frequently is over-
expressed in multidrug resistant cells. For occurrence of 
MDR, a key role was P-gp, which effluxes chemotherapeu-
tic agents out through an ATP-dependent transport leading 
to intracellular deficient drug concentrations.29 Zhang and 
colleagues demonstrated that the SKOV3 cell line did not 
express P-gp, but over-expressed LRP/MVP. However, the 
SKOV3/DDP cell line has been proved to be resistant to 
CDDP and is characterized with high expression of P-gp, 
MRR1, and LRP.30,31 It was also demonstrated that down-
regulation of MDR1 gene expression or inhibiting the func-
tion of MDR1 has a reversal effect on SKOV3/DDP cells, 
which was resistant to DDP.32,31 Our study demonstrated 
that MNPs-Fe3O4 themselves could not lower the protein 
of P-gp, LRP, and MDR1 in SKOV3/DDP cells (p  0.05), 
but they could downregulate the expression of P-gp, LRP, 
and MDR1 protein levels when loaded with DDP. The 
expressions of proteins in the DDP + MNPs-Fe3O4 group 
were also found to be lower than those in DDP-alone 
groups, suggesting that the mechanism of increasing the 
DDP concentration in SKOV3/DDP cell line may be asso-
ciated with the downregulation of expression of MDR1 
gene, MRP1, and LRP.
To further evaluate the role of Bcl-2 family proteins 
in reversal effect of MNPs-Fe3O4 loaded with cisplatin 
on ovarian carcinoma cells, studies were performed using 
SKOV3 as model ovarian cancer cell lines. The Bcl-2 
family proteins represent another class of key regulators 
of cell death and survival. Recent studies have shown that 
therapeutic agents may target proteins of the Bcl-2 family, 
affect mitochondrial outer membrane permeabilization, 
and initiate an apoptotic cell death.33 The dormant period 
of cell increased and enhanced expression of Fas, Fas-L, 
and Bcl-2 protein may be the partial mechanisms of the 
cisplatin-resistance of SKOV3/DDP cells. Li and colleagues 
found that expression of Bcl-2 protein in SKOV3/DDP cells 
was higher than that in SKOV3 cells.16 A more pronounced 
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Figure 4 The expression of Bcl-2 mRNA in sKOV3/DDP cells by different interferences 
for 48 h. Lane 4 was the negative control group; lane 3 was the MNPs-Fe3O4 group; 
lane 2 was the DDP group; and lane 1 was the DDP + MNPs-Fe3O4 group.
4           3            2         1
P-gp     
LRP      
MDR1
β-actin 
Figure 5 The protein of P-gp, LRP, and MDR1 in sKOV3/DDP cells by different 
interferences for 48 h. Lane 1 was the negative control group; lane 2 was the MNPs-
Fe3O4 group; lane 3 was the DDP group; and lane 4 was the DDP+MNPs-Fe3O4 
group. Blots were stripped and re-probed with β-actin to indicate relative amounts 
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difference of Bcl-2 expression and over-expressing of Bcl-2 
were not insensitive to chemotherapy and may have been 
observed in SKOV3/DDP cells had the time been length-
ened as was observed in other studies.16 In contrast, in our 
study, there was only a slight effect on Bcl-2 mRNA in 
the enhanced group, but DDP + MNPs-Fe3O4 reinforced 
downregulation of Bcl-2 mRNA content significantly 
(p  0.05), causing a 70-fold decrease in Bcl-2 mRNA 
level and single use of DDP had less downregulation than 
the same concentration of DDP polymerized with MNPs-
Fe3O4 (p  0.05), suggesting that MNPs-Fe3O4 can enhance 
the action of DDP in downregulation of Bcl-2 mRNA in 
SKOV3/DDP cells.
Conclusions
All these results suggest that MNPs-Fe3O4 can reverse 
DDP resistance to the ovarian carcinoma cell, and the 
mechanism of chemoresistance may be associated with the 
downregulation of MDR1, P-gp, and LRP gene expression, 
which revealed a potential application for reversal of MDR 
in human ovarian cancer cells. The results presented here 
warrant further investigation in animal tumor models and 
eventually in cancer patients.
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